JP2022508825A5 - - Google Patents

Info

Publication number
JP2022508825A5
JP2022508825A5 JP2021546200A JP2021546200A JP2022508825A5 JP 2022508825 A5 JP2022508825 A5 JP 2022508825A5 JP 2021546200 A JP2021546200 A JP 2021546200A JP 2021546200 A JP2021546200 A JP 2021546200A JP 2022508825 A5 JP2022508825 A5 JP 2022508825A5
Authority
JP
Japan
Prior art keywords
sequence
conjugate according
seq
hvr
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546200A
Other languages
English (en)
Japanese (ja)
Other versions
JP7536025B2 (ja
JP2022508825A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056619 external-priority patent/WO2020081744A1/en
Publication of JP2022508825A publication Critical patent/JP2022508825A/ja
Publication of JP2022508825A5 publication Critical patent/JP2022508825A5/ja
Application granted granted Critical
Publication of JP7536025B2 publication Critical patent/JP7536025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546200A 2018-10-17 2019-10-16 免疫調節性ポリヌクレオチドコンジュゲートと使用方法 Active JP7536025B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862747070P 2018-10-17 2018-10-17
US62/747,070 2018-10-17
US201862747611P 2018-10-18 2018-10-18
US62/747,611 2018-10-18
PCT/US2019/056619 WO2020081744A1 (en) 2018-10-17 2019-10-16 Immunomodulating polynucleotide conjugates and methods of use

Publications (3)

Publication Number Publication Date
JP2022508825A JP2022508825A (ja) 2022-01-19
JP2022508825A5 true JP2022508825A5 (cg-RX-API-DMAC10.html) 2022-10-21
JP7536025B2 JP7536025B2 (ja) 2024-08-19

Family

ID=70284225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546200A Active JP7536025B2 (ja) 2018-10-17 2019-10-16 免疫調節性ポリヌクレオチドコンジュゲートと使用方法

Country Status (12)

Country Link
US (1) US20220096649A1 (cg-RX-API-DMAC10.html)
EP (1) EP3866858A4 (cg-RX-API-DMAC10.html)
JP (1) JP7536025B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210102204A (cg-RX-API-DMAC10.html)
CN (1) CN113660955A (cg-RX-API-DMAC10.html)
AU (1) AU2019360216A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021007294A2 (cg-RX-API-DMAC10.html)
CA (1) CA3116880A1 (cg-RX-API-DMAC10.html)
IL (1) IL282282B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021004365A (cg-RX-API-DMAC10.html)
SG (1) SG11202103805SA (cg-RX-API-DMAC10.html)
WO (1) WO2020081744A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
MX2024002187A (es) * 2021-08-20 2024-03-12 Tallac Therapeutics Inc Anticuerpos y conjugados de nectina-4.
TW202328185A (zh) * 2021-08-25 2023-07-16 美商泰勒克療法公司 SIRP-α抗體及結合物
WO2023081934A1 (en) * 2021-11-08 2023-05-11 The University Of Chicago Methods and compositions for pkc-delta inhibition and cancer immunotherapy
KR20250039518A (ko) * 2022-05-18 2025-03-20 탈락 테라퓨틱스, 인크. 항-cd22 항체 올리고뉴클레오타이드 접합체를 사용하여 암을 치료하는 방법
AU2025211114A1 (en) * 2024-01-24 2026-06-18 F. Hoffmann-La Roche Ag Linkers for site-specific protein conjugation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061981A (zh) * 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
CN107109405A (zh) * 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
US20180134802A1 (en) * 2016-01-08 2018-05-17 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
JP2019513692A (ja) * 2016-02-19 2019-05-30 ジェニスフィア・エルエルシー 核酸キャリア及び治療上の使用方法
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها

Similar Documents

Publication Publication Date Title
HRP20201144T1 (hr) Protutijela anti-cd3 i postupci uporabe
CN105585630B (zh) 具有修改的等电点的抗体
JP2024524222A5 (cg-RX-API-DMAC10.html)
JP2020523319A5 (cg-RX-API-DMAC10.html)
JP2023503943A5 (cg-RX-API-DMAC10.html)
JP2020505330A5 (cg-RX-API-DMAC10.html)
EP3774921A1 (en) Antibody variable domains targeting dll3, and use thereof
JP2022521240A5 (cg-RX-API-DMAC10.html)
JP2023528350A5 (cg-RX-API-DMAC10.html)
CA3233246A1 (en) Antibodies targeting baff-r and use thereof
JP2024514530A5 (cg-RX-API-DMAC10.html)
CN113660955A (zh) 免疫调节性多核苷酸缀合物及其使用方法
JP2022550243A5 (cg-RX-API-DMAC10.html)
JP2024520902A5 (cg-RX-API-DMAC10.html)
JP2024535705A5 (cg-RX-API-DMAC10.html)
JP2022535060A (ja) 選択的に切断可能なリンカーを有する二重特異性結合構築物
US20250277024A1 (en) Molecules with multiple binding domains
IL297435A (en) Compounds and methods for modulating atxn1
US20230203198A1 (en) Bispecific binding constructs
CN118974258A (zh) 抗fap-alpha的人源抗体
WO2025151406A1 (en) Chemically modified oligonucleotides and conjugates and methods thereof
WO2025235515A1 (en) Activatable polypeptide complex formulations
TW202602939A (zh) 一種多特異性抗體t細胞銜接器
TW202611077A (zh) 靶向egfr和her2的雙特異性抗體及抗體-藥物偶聯物
WO2025226693A1 (en) Sirp gamma antibodies for treatment of epstein–barr virus infections